Inhibitors of Angiotensin II in Proteinuric Mesangioproliferative Glomerulonephritis

• Status: Completed
• Trial end date: 2008-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates prospectively the effects of an anti-angiotensin II regimen on renal outcome in patients with mesangioproliferative glomerulonephritis followed-up for 10 years.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Magna Graecia
• Treatments: Angiotensin II; Angiotensinogen; Losartan; Ramipril

Criteria

Inclusion Criteria:

• proteinuria ≥ 1 g and < 3 g/24 hours stable during the 3 months of run-in

• microscopic hematuria (with at least 10 red blood cells per high-power field), without other signs or symptoms of systemic diseases stable during the 3 months of run-in

• no-evidence of renal failure or other relevant diseases

• biopsy diagnosis of I-II stage IgA- or pauciimmune-MsPGN

Exclusion Criteria:

• estimated Glomerular Filtration Rate (eGFR) <80 ml/min/1.73m2

• previous immunosuppressive treatment

• blood pressure (BP) >150/90 mmHg